| ReCode Therapeutics–SEVERAL: investment, 202003 financing round Series A $80m co-led by OrbiMed Advisors + Colt Ventures |
2020-03-26 |
| SutroVax–Abingworth: investment, 202003 financing round Series D totalling $110m incl existing + co-investor Abingworth |
2020-03-26 |
| SutroVax–CTI Life Sciences: investment, 202003 financing round Series D totalling $110m incl existing + co-investor CTI Life Sciences |
2020-03-26 |
| SutroVax–Foresite Capital: investment, 202003 financing round Series D totalling $110m incl existing + co-investor Foresite Capital |
2020-03-26 |
| SutroVax–Frazier: investment, 202003 financing round Series D totalling $110m incl existing + co-investor Frazier Health Care Partners |
2020-03-26 |
| SutroVax–Janus Henderson: investment, 202003 financing round Series D totalling $110m incl new + co-lead investor Janus Henderson Investors |
2020-03-26 |
| SutroVax–Longitude Capital: investment, 202003 financing round Series D totalling $110m incl existing + co-investor Longitude Capital |
2020-03-26 |
| SutroVax–Medicxi: investment, 202003 financing round Series D totalling $110m incl existing + co-investor Medicxi |
2020-03-26 |
| SutroVax–Nan Fung: investment, 202003 financing round Series D totalling $110m incl existing + co-investor Pivotal BioVenture Partners |
2020-03-26 |
| SutroVax–RA Capital Management: investment, 202003 financing round Series D totalling $110m incl new + co-lead investor RA Capital Management |
2020-03-26 |
| SutroVax–Roche: investment, 202003 financing round Series D totalling $110m incl existing + co-investor Roche Venture Fund |
2020-03-26 |
| SutroVax–SEVERAL: investment, 202003 financing round Series D $110m co-led by new investors RA Capital + Janus Henderson |
2020-03-26 |
| SutroVax–Texas Pacific Group: investment, 202003 financing round Series D totalling $110m incl existing + co-investor TPG Growth |
2020-03-26 |
| Roche–Forge Therapeutics: antibiotics, 202003– collab research + license option up to $190.5m for FG-LpxC LUNG program for lung infections |
2020-03-25 |
| Immunogenesis–Minapharm: biopharma production, 202003– supply €na cell line + process developm + production of I-O-candidate by ProBiogen AG |
2020-03-24 |
| Astellas–CytomX Therapeutics: antibody cancer drug, 202003– collab $80m upfront + $1.6b milestones + royalties developm bispecific CD3 drugs |
2020-03-23 |
| Bayer–Curadev: STING agonists, 202003– collab research + license agreem incl upfront payment + €250m milestones + single-digit royalties |
2020-03-23 |
| Codexis–Back Bay Life Science Advisors: business consulting, 202003 supply service BBLCA strategic + financial advisor for Codexis in deal with Takeda |
2020-03-23 |
| Takeda–Codexis: gene therapy, 202003– collab + license agreem gene therapies for rare genetic disorders |
2020-03-23 |
| Danaher–Canale Communications: public relations, 202003 service existent for Cepheid by Canale Communciations |
2020-03-21 |
| Koki Holdings–Eppendorf: investment, 202003– acquisition €na of Koki’s Centrifuge + Processing business by Eppendorf from KKR |
2020-03-19 |
| BMS–Oxford BioMedica: lentiviral vector technology, 202003– license non-excl + supply agreem LentiVector for CAR-T + TCR-T therapeutics of Juno |
2020-03-18 |
| Immatics–Arya Sciences: investment, 202003 reverse merger resulting in Nasdaq-listing of Immatics + $148m cash held by Arya |
2020-03-17 |
| Immatics–SEVERAL: investment, 202003 common stock PIPE $104m led by Perceptive Advisors |
2020-03-17 |
| MolMed–Asahi Glass: investment, 202003– cash tender offer €240m for 463.5m shares at €0.518/share by AGC Inc ANNOUNCED |
2020-03-17 |
| Pfizer–BioNTech: mRNA-based vaccines, 202003– collab development of COVID-19 vaccine |
2020-03-17 |
| Sigilon Therapeutics–SEVERAL: investment, 202003 financing round Series B $80.3m with CPP Investments + Longevity Vision Fund + BlackRock et al. |
2020-03-17 |
| Sigilon Therapeutics–Ten Bridge Communications: public relations, 202003 service existent media relations by Ten Bridge |
2020-03-17 |
| Fosun–BioNTech: mRNA-based vaccines, 202003– collab up to €120m + profit sharing development of COVID-19 vaccine in China with Fosun Pharma |
2020-03-16 |
| Tempus Labs–Baillie Gifford: investment, 202003 financing round Series G totalling $100m incl investor Baillie Gifford |
2020-03-13 |
| Tempus Labs–Franklin Templeton: investment, 202003 financing round Series G totalling $100m incl investor Franklin Templeton |
2020-03-13 |
| Tempus Labs–New Enterprise Associates: investment, 202003 financing round Series G totalling $100m incl investor NEA |
2020-03-13 |
| Tempus Labs–Novo Group: investment, 202003 financing round Series G totalling $100m incl investor Novo Holdings |
2020-03-13 |
| Tempus Labs–SEVERAL: investment, 202003 financing round Series G $100m incl Baillie Gifford + Franklin Templeton + NEA + Novo Holdings + T Rowe Price |
2020-03-13 |
| Tempus Labs–T Rowe Price: investment, 202003 financing round Series G totalling $100m incl funds + accounts managed by T Rowe Price |
2020-03-13 |
| Life Sciences Partners–BMS: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor BMS |
2020-03-10 |
| Life Sciences Partners–EU (govt): investment, 202003 final closing totalling €600m of LSP 6 fund incl investor EIF |
2020-03-10 |
| Life Sciences Partners–Otsuka: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor Otsuka Pharmaceutical |
2020-03-10 |
| Life Sciences Partners–SEVERAL: investment, 202003 final closing €600m of LSP 6 fund with investors incl BMS + Otsuka + EIF |
2020-03-10 |
| Calixar–SEVERAL: investment, 202003 second financing round €2.5m |
2020-03-09 |
| Numab–MacDougall Biomedical Communications: public relations, 202003 service existent by MacDougall |
2020-03-09 |
| Zogenix–LifeSci: public relations, 202003 supply service existent investor relations by LifeSci Advisors |
2020-03-06 |
| Zogenix–SEVERAL: investment, 202003 public offering $200.22m+30.03m with 8.52m+1.278m shares common stock at $23.5/share |
2020-03-06 |
| Biotalys–Novalis LifeSciences: investment, 202003 financing round Series C 2nd closing totalling €10m incl new investor Novalis LifeSciences |
2020-03-05 |
| Biotalys–SEVERAL: investment, 202003 financing round Series C €10m 2nd closing bringing total Series C to €45m |
2020-03-05 |
| BenchSci–Alphabet: investment, 202002 financing round Series B totalling $22m incl existing + co-investor Gradient Ventures |
2020-03-04 |
| BMS–Voluntis: digital therapeutics, 202003–collab developm of digital therapeutics using Theraxium Oncology platform |
2020-03-03 |
| Qiagen–Barclays: financial services, 202003 supply service Barclays Bank plc is financial advisor w regard to acquisition by Thermo Fisher |
2020-03-03 |
| Qiagen–De Brauw Blackstone Westbroek: legal services, 202003 supply service De Brauw BW NV is legal counsel w regard to acquisition by Thermo Fisher |
2020-03-03 |
| Qiagen–Goldman Sachs: financial services, 202003 supply service Goldman Sachs Intl is lead financial advisor w regard to acquisition by Thermo Fisher |
2020-03-03 |
| Qiagen–Linklaters: legal services, 202003 supply service Linklaters LLP is legal counsel w regard to acquisition by Thermo Fisher |
2020-03-03 |
| Qiagen–Mintz Levin Cohn: legal services, 202003 supply service Mintz Levin Cohn FGP is legal counsel w regard to acquisition by Thermo Fisher |
2020-03-03 |
| Qiagen–Thermo Fisher: investment, 202003– acquisition €9.14b cash tender offer at €39/share ANNOUNCED |
2020-03-03 |
| Thermo Fisher–JPMorgan Chase: financial services, 202003 supply service JP Morgan Securities LLC is financial advisor w regard to Qiagen acquisition |
2020-03-03 |
| Thermo Fisher–Morgan Stanley: financial services, 202003 supply service Morgan Stanley & Co LLC is financial advisor w regard to Qiagen acquisition |
2020-03-03 |
| Thermo Fisher–Wachtel Lipton Rosen & Katz: legal services, 202003 legal council to Thermo Fisher with regard to acquisition of Qiagen |
2020-03-03 |
| Agilent–Visiopharm: image analysis software, 202003– collab co-marketing of Visiopharm’s AI-driven solutions for digital pathology |
2020-03-02 |
| Evonetix–SEVERAL: investment, 202003 financing round Series B $30m (£23m) led by new investor Foresite Capital |
2020-03-02 |
| Forty Seven–Gilead: investment, 202003– acquisition $4.9b cash tender offer at $95.5/share |
2020-03-02 |
| Immunocore–General Atlantic: investment, 202003 financing round Series B totalling $130m incl new + lead investor General Atlantic |
2020-03-02 |
| Immunocore–SEVERAL: investment, 202003 financing round Series B $130m led by new investor General Atlantic |
2020-03-02 |
| Sterling Pharma Solutions–Thermo Fisher: LC system, 202003 supply early customer for Vanquish Core HPLC System |
2020-03-02 |
| Danaher–Sherlock Biosciences: molecular diagnostics, 202002– collab developm of Cepheid GeneXpert tests using CRISPR-based SHERLOCK technology |
2020-02-28 |
| Sherlock Biosciences–1AB Media: public relations, 202002 service existent media relations by 1AB Media |
2020-02-28 |
| Boehringer–Trutino Biosciences: cancer immunotherapy, 202002– collab research + ww excl license to develop up to 3 candidates using ODC technology |
2020-02-27 |
| Centogene–Coulter Partners: recruitment services, 202002 supply service placement of Philip Lambert as CSO at Centogen based in US |
2020-02-26 |
| FinnGen–AbbVie: genomics, 202002 collab existent AbbVie is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–Biogen: genomics, 202002 collab existent Biogen is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–BMS: genomics, 202002 collab existent BMS is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–JnJ: genomics, 202002– collab Janssen new industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–Maze Therapeutics: genomics, 202002– collab Maze new industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–Merck (US): genomics, 202002 collab existent MSD is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–Pfizer: genomics, 202002 collab existent Pfizer is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–Roche: genomics, 202002 collab existent Genentech is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| Roche–Bicycle Therapeutics: small-molecule drugs, 202002– collab strategic $30m upfront + up to $1.7b r+d of bicycle peptides for cancer Genentech |
2020-02-25 |
| GSK–Immatics: cell therapy, 202002– strategic collab $45m upfront + $1.1b milestones for first two TCR therapeutics programmes + royalties |
2020-02-20 |
| Forte Biosciences–Alger: investment, 202002– financing round totalling $14m incl investor Alger |
2020-02-19 |
| Forte Biosciences–BVF Partners: investment, 202002– financing round totalling $14m incl investor BVF Partners LP |
2020-02-19 |
| Forte Biosciences–OrbiMed: investment, 202002– financing round totalling $14m incl investor OrbiMed |
2020-02-19 |
| Forte Biosciences–SEVERAL: investment, 202002– financing round $14m conditional on completion of reverse merger with Tocagen |
2020-02-19 |
| Forte Biosciences–Tocagen: investment, 202002– reverse merger in shares with Forte shareholders holding 74.5% of combined company |
2020-02-19 |
| Servier–Cellectis: T-cell immunotherapy, 202002– collab amendment + expansion ww excl license to develop + commercialise UCARTs tageting CD19 |
2020-02-18 |
| OMass–SEVERAL: investment, 202002 financing round Series A extension £27.5m bringing total Series A to £41.5m |
2020-02-17 |
| NanoPin Technologies–Thermo Fisher: mass spectrometry, 202002– collab developm LC-MS-based workflows for blood-based infectious disease diagnostics |
2020-02-13 |
| Stilla Technologies–BNP Paribas: investment, 202002 financing round Series B totalling €20m incl existing investor BNP Paribas Développement |
2020-02-11 |
| Stilla Technologies–Eurazeo: investment, 202002 financing round Series B totalling €20m incl existing investor Idinvest Partners |
2020-02-11 |
| Stilla Technologies–Illumina: investment, 202002 financing round Series B totalling €20m incl existing investor Illumina Ventures |
2020-02-11 |
| Stilla Technologies–Kurma: investment, 202002 financing round Series B totalling €20m incl existing investor Kurma Partners |
2020-02-11 |
| Stilla Technologies–LBO France: investment, 202002 financing round Series B totalling €20m incl existing investor LBO France |
2020-02-11 |
| Stilla Technologies–Paris Saclay Seeds: investment, 202002 financing round Series B totalling €20m incl existing investor Paris Saclay Seed Funds |
2020-02-11 |
| Stilla Technologies–SEVERAL: investment, 202002 financing round Series B €20m with new investor TUS-Holdings alongside existing investors |
2020-02-11 |
| Stilla Technologies–TUS-Holdings: investment, 202002 financing round Series B totalling €20m incl new investor CLIIF Investment Fund of Tuspark Europe |
2020-02-11 |
| Orphazyme–SEVERAL: investment, 202002 directed issue + private placement DKK745m (€100m) of 7m new + existing shares |
2020-02-07 |
| Aimmune Therapeutics–Nestlé: investment, 202002 equity investment $200m by Nestlé Health Science results in 19.9% common stock + 25.6% fully diluted |
2020-02-05 |
| MaaT Pharma–BPCE: investment, 202002 financing round Series B totalling €18m incl existing investor Seventure Partners |
2020-02-05 |
| MaaT Pharma–Crédit Mutuel-CIC: investment, 202002 financing round Series B totalling €18m incl existing investor Crédit Mutuel Innovation |
2020-02-05 |
| MaaT Pharma–SEVERAL: investment, 202002 financing round Series B €18m with SymBiosis + Seventure + Crédit Mutuel Innovation + Biocodex et al. |
2020-02-05 |
| MaaT Pharma–SymBiosis LLC: investment, 202002 financing round Series B totalling €18m incl new investor SymBiosis LLC |
2020-02-05 |
| BenchSci–F-Prime Capital: investment, 202002 financing round Series B totalling $22m incl new + lead investor F-Prime Capital |
2020-02-04 |
| BenchSci–Golden Ventures: investment, 202002 financing round Series B totalling $22m incl existing + co-investor Golden Ventures |
2020-02-04 |
![[LSUS] Life-Sciences-USA.com - The Transatlantic Life Sciences Web Portal](/images/basics/lsus-life-sciences-usa-portal-logo-2019.png){kind=logo}
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 120x600px](/banner/iito-20181119-120-600-msc-mass-spec-capital-com.jpg)
